Hyaluronic acid-guided assembly of ceria nanozymes as plaque-targeting ROS scavengers for anti-atherosclerotic therapy.

Oxidative stress is a distinguishing feature in atherosclerosis disease. Reactive oxygen species (ROS) can increase the oxidized low density lipoprotein (ox-LDL) and oxidative damage to macrophages in the plaque. Although antioxidant agents such as N-acetylcysteine are used to treat atherosclerosis, but provide a poor clinical benefit to the majority of patients with atherosclerosis. Here we have designed hyaluronic acid-guided assemblies of ceria nanozymes (HA-CeO NPs) as novel plaque-targeting ROS scavengers. The introduction of hyaluronic acid not only provide the stability and biocompatibility, but also surprisingly enhance SOD-mimic activities of ceria nanozymes compared to bare CeO precipitates, dextran or poly-aspartic acid coated ceria nanozymes. Interestingly, we find HA-CeO NPs not only actively target plaque-associated macrophages in atherosclerosis to remove superfluous ROS and protect macrophages from ROS-caused damages, but also effectively inhibit endocytosis of ox-LDL by activated macrophages. We believe HA-CeO nanozymes can serve as a simple and promising platform for anti-atherosclerotic therapy.